Insider Cluster (2 insiders) ·Filed Jun 8, 2026

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $744K total
Actionable Insight • Neutral

This cluster carries no actionable signal. The sales are mechanically tied to option exercises/vesting and are negligible relative to Teva's market cap. Monitor next 10-Q for fundamental performance rather than insider flows.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
TEVA ▲ +8.47% at T+60d
NEUTRAL call ✓ call won +8.47% · α vs SPY +4.65% · entry $34.45 → $37.37
Entry anchored
Jun 8, 03:59 PM ET
via exchange tick
T+1d
-2.53%
call -2.53% · α -0.95%
$33.58
settled 4mo ago
T+5d
-2.21%
call -2.21% · α -4.62%
$33.69
settled 4mo ago
T+20d
+0.58%
call +0.58% · α -0.87%
$34.65
settled 3mo ago
T+60d
+8.47%
call +8.47% · α +4.65%
$37.37
settled 4w ago

Price Chart

Loading chart...

Executive Summary

Two senior Teva executives, the CEO and an EVP, sold a combined $744K in open-market stock over a three-day window alongside multiple directors exercising zero-strike derivatives. At $39.8B market cap, the $744K represents 0.0019% of equity — trivially small. The derivative exercises by directors are non-cash events with zero economic signal. The cluster is a routine vesting-and-sell pattern, not a material insider signal.

Key Financial Metrics

Direction
selling
Total Value
$744.0K
Insiders
2

Key Facts

  • CEO Francis Richard D sold 6,153 shares on June 5, 2026 at $34.35 for ~$211K — a fraction of his total holdings
  • EVP Shields Matthew sold 16,195 shares on June 3, 2026 at $32.87 for ~$532K
  • Six directors exercised zero-strike derivatives for 14,492 shares each — non-cash, zero economic signal
  • Total cluster value of $744K is only 0.0019% of Teva's $39.8B market cap
  • Shields' sale directly followed and matched his derivative exercise, consistent with cashless vesting

Financial Impact

$744K total insider sales against $39.8B market cap — immaterial

insider-ownership dillutiondilution

Risk Factors

  • Insider selling at $34.35 near recent highs could precede broader weakness, but dollar amount is too small to read meaningfully
  • CEO sale, though small, is the first open-market sale from this insider in the available window worth noting

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TEVA-1780949085079
31 reports for TEVA
Performance horizon
100% Hit rate 9 of 9 directional calls best @ T+20▲ +17.61%Jul 20, 2026
Filters
Rows
Reports for TEVA — sortable, filterable
TypeNow
Sep 10, 2026
22d ago
Press Release
NEUTRAL ★ 5/10
$36.35 $39.19▲ +7.81%▲ +8.31%$39.51 (+8.69%)
Sep 8, 2026
24d ago
424B5
NEUTRAL ★ 5/10
$36.76 $39.25▲ +6.77%▲ +7.89%$39.51 (+7.48%)
Sep 2, 2026
4w ago
Court Ruling
NEUTRAL ★ 1/10
$37.49 $36.35▼ −3.04%▼ −2.08%$39.51 (+5.39%)
Aug 28, 2026
5w ago
Press Release
BULLISH ★ 6/10
$36.44 $36.36▼ −0.22%▼ −0.33%$39.51 (+8.42%)
Aug 25, 2026
5w ago
Court Ruling
NEUTRAL ★ 2/10
$38.10 $36.20▼ −4.99%▼ −4.46%$39.51 (+3.70%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$38.10 $36.20▼ −4.99%▼ −4.46%$39.51 (+3.70%)
Aug 10, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$36.14 $36.46▲ +0.89%▲ +0.93%$39.51 (+9.32%)
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$34.81 $36.45▲ +4.70%▲ +3.49%$39.51 (+13.50%)
Jul 31, 2026
9w ago
Court Ruling
BULLISH ★ 7/10
$35.01 $35.36▲ +1.00%▼ −2.51%$39.51 (+12.85%)
Jul 29, 2026
9w ago
8-K
MIXED ★ 5/10
$34.71 $34.72▲ +0.03%▼ −5.50%$39.51 (+13.83%)
Showing 10 of 31

US Market Status

Market Open — Closes in 2h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 8, 2026